Hepatocellular carcinoma medical therapy: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| Line 37: | Line 37: | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
*[[Chemotherapy adjuvant]] | *[[Chemotherapy adjuvant]] | ||
:Oral synthetic retinoid for 12 months after [[resection]]/[[ablation]] maybe helpful in the treatment of hepatocellular carcinoma.<ref>[http://www.asco.org/ac/1,1003,_12-002626-00_18-0034-00_19-0027,00.asp] American Society of Clinical Oncology, 2005 Annual Meeting, Abstracts on Hepatobiliary Cancer</ref> | :*Oral synthetic retinoid for 12 months after [[resection]]/[[ablation]] maybe helpful in the treatment of hepatocellular carcinoma.<ref>[http://www.asco.org/ac/1,1003,_12-002626-00_18-0034-00_19-0027,00.asp] American Society of Clinical Oncology, 2005 Annual Meeting, Abstracts on Hepatobiliary Cancer</ref> | ||
*[[Palliative]] | *[[Palliative]] | ||
:Regimens that included [[doxorubicin]], [[cisplatin]], [[fluorouracil]], [[interferon]], [[epirubicin]], or [[taxol]], as a single agent or in combination, did not show any survival benefit (Response rate, 0%-25%); a few isolated major responses allowed patients to undergo partial hepatectomy. | :*Regimens that included [[doxorubicin]], [[cisplatin]], [[fluorouracil]], [[interferon]], [[epirubicin]], or [[taxol]], as a single agent or in combination, did not show any survival benefit (Response rate, 0%-25%); a few isolated major responses allowed patients to undergo partial hepatectomy. | ||
====Interventional radiology==== | ====Interventional radiology==== | ||
Revision as of 15:29, 11 September 2015
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [2] Associate Editor(s)-in-Chief: Mohamad Alkateb, MBBCh [3]
|
Hepatocellular carcinoma Microchapters |
|
Differentiating Hepatocellular carcinoma from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Hepatocellular carcinoma medical therapy On the Web |
|
American Roentgen Ray Society Images of Hepatocellular carcinoma medical therapy |
|
Risk calculators and risk factors for Hepatocellular carcinoma medical therapy |
Overview
Patients with hepatocellular carcinoma are treated with ethanol injections, transcatheter arterial chemoembolization (TACE), sealed source radiotherapy, radiofrequency ablation (RFA), intra-arterial iodine-131-lipiodol administration, high intensity focused ultrasound (HIFU), hormonal therapy, and chemotherapy.
Medical Therapy
Contraindicated medications
Hepatocellular carcinoma is considered an absolute contraindication to the use of the following medications:
- Drospirenone and Ethinyl estradiol
- Norethindrone acetate and Ethinyl estradiol
- Norgestimate and Ethinyl estradiol
- Norgestrel and Ethinyl estradiol
- Hydroxyprogesterone caproate
Medical therapy for hepatocellular carcinoma
Percutaneous ethanol injection
- Percutaneous ethanol injection (PEI) well tolerated. It's preferred in small (< 3 cm) solitary tumors.
Transcatheter arterial chemoembolization (TACE)
- Transcatheter arterial chemoembolization (TACE) is usually performed in the treatment of large tumors (larger than 3 cm and less than 4 cm in diameter), most frequently by intraarterially injecting an infusion of antineoplastic agents mixed with iodized oil (such as Lipiodol).
- Combined PEI and TACE can be used for tumors larger than 4 cm in diameter.
Sealed source radiotherapy
- Sealed source radiotherapy can be used to destroy the tumor from within (thus minimizing exposure to healthy tissue). TheraSphere is an FDA approved treatment which has been shown in clinical trials to increase survival rate of low-risk patients. This method uses a catheter (inserted by a radiologist) to deposit radioactive particles to the area of interest.
Radiofrequency ablation (RFA)
- Radiofrequency ablation (RFA) uses high frequency radio-waves to ablate the tumour.
Intra-arterial iodine-131–lipiodol administration
- Intra-arterial iodine-131–lipiodol administration Efficacy demonstrated in unresectable patients, those with portal vein thrombus. This treatment is also used as adjuvant therapy in resected patients. It is believed to raise the 3-year survival rate from 46 to 86%.
High intensity focused ultrasound (HIFU)
- High intensity focused ultrasound (HIFU) is a new technique which uses much very powerful ultrasound to treat the tumour. Still at a very experimental stage. Most of the work has been done in China. Some early work is being done in Oxford and London in the UK.
Hormonal therapy
- Hormonal therapy with Antiestrogen therapy and tamoxifen can be used in hepatocellular treatment.
Chemotherapy
- Regimens that included doxorubicin, cisplatin, fluorouracil, interferon, epirubicin, or taxol, as a single agent or in combination, did not show any survival benefit (Response rate, 0%-25%); a few isolated major responses allowed patients to undergo partial hepatectomy.
Interventional radiology
- Intervention radiology may help in hepatocellular carcinoma treatment.
The effectiveness of medical therapy is related to the following:
- Size
- Involvement of liver vessels
- Presence of a tumor capsule
- Presence of extrahepatic metastases
- Presence of daughter nodules
- Vascularity of the tumor